New IBS treatment shows potential in Phase 2 study

(American Gastroenterological Association) Patients with diarrhea-predominant irritable bowel syndrome, or IBS-D, treated with eluxadoline achieved better clinical response and experienced more symptom improvement than those using placebo, according to a recent study in Gastroenterology, the official journal of the American Gastroenterological Association.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news